Compounds are provided having the following structure: [Formula should be inserted here] or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R.sup.3, L.sup.1, L.sup.2, G.sup.1, G.sup.2 and G.sup.3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided. ##STR00001##

The compositions of the present invention comprise at least one medium polarity oil and at least one antibacterial agent, the combination of which produces a synergistic antibacterial effect against bacterial biofilms. Methods are disclosed for the reduction of bacteria in and/or elimination of bacterial biofilms on biological and non-biological surfaces, as well as methods for the treatment of wounds, skin lesions, mucous membrane lesions, and other biological surfaces infected or contaminated with bacterial biofilms.

The compositions of the present invention comprise at least one medium polarity oil and at least one antibacterial agent, the combination of which produces a synergistic antibacterial effect against bacterial biofilms. Methods are disclosed for the reduction of bacteria in and/or elimination of bacterial biofilms on biological and non-biological surfaces, as well as methods for the treatment of wounds, skin lesions, mucous membrane lesions, and other biological surfaces infected or contaminated with bacterial biofilms.

The compositions of the present invention comprise at least one medium polarity oil and at least one antibacterial agent, the combination of which produces a synergistic antibacterial effect against bacterial biofilms. Methods are disclosed for the reduction of bacteria in and/or elimination of bacterial biofilms on biological and non-biological surfaces, as well as methods for the treatment of wounds, skin lesions, mucous membrane lesions, and other biological surfaces infected or contaminated with bacterial biofilms.

The present disclosure provides the use of sodium octanoate in preparation of a medicine for improving the efficacy of cardiopulmonary resuscitation and post-resuscitation multiple organ dysfunction, and relates to the technical field of pharmaceutical preparation. The above medicine for improving the efficacy of cardiopulmonary resuscitation and post-resuscitation multiple organ dysfunction comprises the administration of a pharmaceutically effective dose of sodium octanoate. By administering a pharmaceutically effective dose of sodium octanoate that is used for promoting fatty acid oxidation energy supply during systemic ischemia-reperfusion injury caused by cardiac arrest and resuscitation, this medicine can further effectively improve the efficacy of cardiopulmonary resuscitation and post-resuscitation multiple organ dysfunction.

Invention pertains to a free-flowing particulate powder including 2-90 wt. % of an active compound on a carrier, wherein the carrier has a D(v,0.1) of at least 100 microns, with the active compound being selected from lactylate in accordance with formula (1), Formula (1): R2-COO—[—CH(CH3)-COO]n-R1 or a Na, K, Ca, Mg, Fe(II), Zn, NH4, or Cu(II) salt thereof, a glycolylate of formula (2), Formula (2): R2-COO—[—CH2-COO]n-R1 or a Na, K, Ca, Mg, Fe(II), Zn, NH4, or Cu(II) salt thereof a lactate ester of formula (3), Formula (3): HO—CH(CH3)-COO—R2 and/or a glycolic acid ester of formula (4), Formula (4): HO—CH2-COO—R2 wherein in the above formulae R1 is selected from H, n stands for an integer with a value of 1-10, and R2 stands for a C1-C35 alkyl or alkenyl chain which may be branched or unbranched. The powder allows easy provision of the active compound to feed compositions.

Invention pertains to a free-flowing particulate powder including 2-90 wt. % of an active compound on a carrier, wherein the carrier has a D(v,0.1) of at least 100 microns, with the active compound being selected from lactylate in accordance with formula (1), Formula (1): R2-COO—[—CH(CH3)-COO]n-R1 or a Na, K, Ca, Mg, Fe(II), Zn, NH4, or Cu(II) salt thereof, a glycolylate of formula (2), Formula (2): R2-COO—[—CH2-COO]n-R1 or a Na, K, Ca, Mg, Fe(II), Zn, NH4, or Cu(II) salt thereof a lactate ester of formula (3), Formula (3): HO—CH(CH3)-COO—R2 and/or a glycolic acid ester of formula (4), Formula (4): HO—CH2-COO—R2 wherein in the above formulae R1 is selected from H, n stands for an integer with a value of 1-10, and R2 stands for a C1-C35 alkyl or alkenyl chain which may be branched or unbranched. The powder allows easy provision of the active compound to feed compositions.

Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid ester (e.g., isopropyl myristate), optionally comprising an ointment base such as a hydrocarbon base (e.g., petroleum jelly) and/or an organic alcohol (e.g., propylene glycol), that, when topically applied to the skin, locally delivers a therapeutically effective amount of the PFPRA compound to subcutaneous fat under the skin, and methods of preparation. The therapeutic effect is, for example, reduction of the subcutaneous fat under the skin. Further provided are methods of reducing body fat in a subject comprising topically administering the composition to the subject.

Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid ester (e.g., isopropyl myristate), optionally comprising an ointment base such as a hydrocarbon base (e.g., petroleum jelly) and/or an organic alcohol (e.g., propylene glycol), that, when topically applied to the skin, locally delivers a therapeutically effective amount of the PFPRA compound to subcutaneous fat under the skin, and methods of preparation. The therapeutic effect is, for example, reduction of the subcutaneous fat under the skin. Further provided are methods of reducing body fat in a subject comprising topically administering the composition to the subject.

Antimicrobial polymer coating formulations are prepared that protect biological surfaces by treating, reducing, ameliorating, preventing or inhibiting pathogenic microorganism ingress to a human or animal host, reducing the potential for infection, particularly by necrotizing fasciitis originating microorganisms, through use of a polymer coating barrier containing antimicrobial agents that facilitates sustained release of biocidal agents active against such opportunistic microorganisms. Such formulations are effective for inhibiting microbial ingress pertaining to soft tissue and skin tears, abrasions, punctures and surgical wounds, and can be used as in water environments and as a skin protectant sunscreen and insect repellent.